[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-364579-105":59,"doc-detail-364579-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","unveiling-the-intriguing-relationship-oncogenic-kras-morphological-shifts-and-mutational-complexity-in-pancreatic-mucinous-cystic-neoplasms","Unveiling the intriguing relationship: oncogenic KRAS, morphological shifts, and mutational complexity in pancreatic mucinous cystic neoplasms","","Pancreatic ductal adenocarcinoma (PDAC) frequently develops from preexisting cystic precursor lesions such as intraductal papillary mucinous neoplasms (IPMN) and mucinous cystic neoplasms (MCN). This brief report characterizes molecular heterogeneity and the mutational landscape of MCN in relation to PDAC, emphasizing the role of KRAS mutations in tumor progression. Using targeted next-generation sequencing on low-grade MCN and invasive PDAC, the study identifies overlapping mutational profiles, especially KRAS, TP53, and FBXW7. It reports that 69.2% of MCN carry somatic mutations and that KRAS-driven changes show higher variant allele frequencies in PDAC. Histology across additional MCN cases reveals intratumor heterogeneity linking variant KRAS distributions to cellular morphologies and dysplastic features. The report further assesses liquid biopsy utility by demonstrating 71.4% concordance for KRAS detection in circulating tumor DNA compared with tissue biopsies, supporting KRAS evaluation for pancreatic lesion stratification and therapeutic decision-making.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/unveiling-the-intriguing-relationship-oncogenic-kras-morphological-shifts-and-mutational-complexity-in-pancreatic-mucinous-cystic-neoplasms/364579/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/unveiling-the-intriguing-relationship-oncogenic-kras-morphological-shifts-and-mutational-complexity-in-pancreatic-mucinous-cystic-neoplasms/364579.png","ImageObject",300,407,{"name":92,"@type":93},"Ezra","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-19","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What precursor lesions are discussed for PDAC development?","Question",{"text":112,"@type":113},"The study discusses PDAC arising from preexisting cystic lesions, including intraductal papillary mucinous neoplasms (IPMN) and mucinous cystic neoplasms (MCN).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which genes show key mutational overlap between MCN and PDAC?",{"text":117,"@type":113},"Targeted sequencing highlights substantial overlap in mutational profiles, particularly KRAS, TP53, and FBXW7 mutations.",{"name":119,"@type":110,"acceptedAnswer":120},"How is KRAS mutation detection evaluated, and what concordance is reported?",{"text":121,"@type":113},"KRAS detection is assessed using circulating tumor DNA (ctDNA) compared with tissue biopsies, with a reported concordance rate of 71.4% for KRAS mutation detection across cohorts.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},364579,1790196195,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Journal of Pathology  \nJ Pathol April 2025; 265: 401–407  \nPublished online 5 February 2025 in Wiley Online Library (wi[leyonlinelibrary.com](leyonlinelibrary.com) DOI: 10.1002/path.6397)[)](leyonlinelibrary.com) DOI: 10.1002/path.6397)[ DOI:](leyonlinelibrary.com) DOI: 10.1002/path.6397)[ 10.1002/path.6397](leyonlinelibrary.com) DOI: 10.1002/path.6397)  \nBRIEF REPORT  \nUnveiling the intriguing relationship: oncogenic KRAS, morphological shifts, and mutational complexity in pancreatic mucinous cystic neoplasms  \nLucas-Alexander Schulte 1 , Annika Beck2, Ralf Marienfeld2, Ninel Azoitei3, Thomas FE Barth2, Alica Beutel4,  \nVladimir Benes5, Markus W Büchler6, Nadine Therese Gaisa2, Katja Kilani 1 , Nathalia Giese7, Christoph W Michalski6,  \nPeter Möller2, Lukas Perkhofer 1 , Tobias Rausch5, Thomas Seufferlein4, Peter Schirmacher9, Andreas Alexander Kleger 1,3*†  \nStefan Repky8, Elodie Roger3, Jeanette Scheible3, Wolfgang Berger4,10, Thilo Hackert6,11† and  \n1 Division of Interdisciplinary Pancreatology, Department of Internal Medicine 1, Ulm University Hospital, Ulm, Germany  \n2 Department of Pathology, Ulm University Hospital, Ulm, Germany  \n3 Institute of Molecular Oncology and Stem Cell Biology (IMOS), Ulm University Hospital, Ulm, Germany  \n4 Department of Internal Medicine 1, Ulm University Hospital, Ulm, Germany  \n5 Genomics Core Facility, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany  \n6 Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany  \n7 EPZ-Biobank, Division of Pancreatic Cancer Research, Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany  \n8 Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany  \n9 Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany  \n10 Evangelisches Krankenhaus Königin Elisabeth Herzberge, Department of Gastroenterology, Berlin, Germany  \n11 Department of General Surgery, University Hospital Hamburg Eppendorf, Hamburg, Germany  \n*Correspondence to: A Kleger, Director, Institute of Molecular Oncology and Stem Cell Biology, Division Chief, Interdisciplinary Pancreatology, Department of Internal Medicine 1, Ulm University Hospital, Albert-Einstein-Allee 23, D-89081 Ulm, Germany. E-mail: alexander.kleger@uni-ulm.de †These authors jointly supervised this work.  \nAbstract  \nPancreatic ductal adenocarcinoma (PDAC) often arises from preexisting cystic lesions such as intraductal papillary mucinous neoplasms (IPMN) and mucinous cystic neoplasms (MCN). This study investigated the molecular heterogeneity and mutational landscape of MCN in relation to PDAC, highlighting the signiﬁcance of KRAS mutations in tumor progression. Utilizing targeted next-generation sequencing on low-grade MCN and invasive PDAC samples, weidentiﬁed a substantial overlap in mutational proﬁles, particularly mutations in KRAS, TP53, and FBXW7.  \nSpeciﬁcally, 69.2% of MCN exhibited somatic mutations, with KRAS mutations being a predominant oncogenicdriver. The characterization of mutant versus wildtype KRAS variant allele frequencies (VAF) indicated higher mutation levels in PDAC compared to MCN, suggesting an evolutionary trajectory toward malignancy. Further histological analysis of 12 additional MCN cases revealed signiﬁcant intratumor heterogeneity, with variant KRAS mutation distributions correlating with distinct cellular morphologies and dysplastic features. Additionally, we explored the potential of liquid biopsies, demonstrating a concordance rate of 71.4% for KRAS mutation detection in circulating tumor DNA (ctDNA) relative to tissue biopsies across cohorts. Our ﬁndings underscore the relevance of evaluating KRAS mutations—herein referred to as VAF per microdissected region—as they relate to histopathological markers of dysplasia, contributing to improved stratiﬁcation of pancreatic lesions and facilitating personalized treatment strategies. In conclus","cbCaiom6yA6haJI1","https://ap.wps.com/l/cbCaiom6yA6haJI1","pdf",913834,"English","# Abstract\n# Introduction\n# Results (implied by study aims and sequencing, histology, and liquid biopsy analyses)\n# Conclusions (implied by final summary statements)","[{\"question\":\"What precursor lesions are discussed for PDAC development?\",\"answer\":\"The study discusses PDAC arising from preexisting cystic lesions, including intraductal papillary mucinous neoplasms (IPMN) and mucinous cystic neoplasms (MCN).\"},{\"question\":\"Which genes show key mutational overlap between MCN and PDAC?\",\"answer\":\"Targeted sequencing highlights substantial overlap in mutational profiles, particularly KRAS, TP53, and FBXW7 mutations.\"},{\"question\":\"How is KRAS mutation detection evaluated, and what concordance is reported?\",\"answer\":\"KRAS detection is assessed using circulating tumor DNA (ctDNA) compared with tissue biopsies, with a reported concordance rate of 71.4% for KRAS mutation detection across cohorts.\"}]","Unveiling the intriguing relationship: oncogenic KRAS, morphological shifts, and mutational complexity in pancreatic mucinous cystic neoplasms | PDF",1790158336,18,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d2347200e3b7bb7a8e3fcdd74fa21e68.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/758b8da8bd0c22c8de143ecc05204a56.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2c7c1acd3cc99f8175b045abafaaa926.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d13e4f7dcfd941d45cf1cf5beebc973a.webp",980,1385]